Literature DB >> 15315477

Vif is an auxiliary factor of the HIV-1 reverse transcriptase and facilitates abasic site bypass.

Reynel Cancio1, Silvio Spadari, Giovanni Maga.   

Abstract

The HIV-1 accessory protein Vif was found to modulate the RNA- and DNA-dependent DNA synthesis activity of the viral RT (reverse transcriptase) in two ways: (i) it stimulated the binding of the viral RT to the primer by increasing the association rate kcat/K(m) and by decreasing the thermodynamic barrier DeltaH([ES]) for complex formation, and (ii) it increased the polymerization rate of HIV-1 RT. A Vif mutant lacking the final 56 amino acids at the C-terminus failed to stimulate the viral RT. On the other hand, another Vif mutant lacking the first 43 amino acids at the N-terminus, which are involved in RNA binding and interaction with the viral protease, was able to stimulate RT activity. In addition, Vif was found to promote the bypass of an abasic site by HIV-1 RT.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15315477      PMCID: PMC1133740          DOI: 10.1042/BJ20040914

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  29 in total

Review 1.  Cell-dependent function of HIV-1 Vif for virus replication (Review).

Authors:  R Inubushi; A Adachi
Journal:  Int J Mol Med       Date:  1999-05       Impact factor: 4.101

2.  Selective interaction of the human immunodeficiency virus type 1 reverse transcriptase nonnucleoside inhibitor efavirenz and its thio-substituted analog with different enzyme-substrate complexes.

Authors:  G Maga; D Ubiali; R Salvetti; M Pregnolato; S Spadari
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

3.  Partial rescue of the Vif-negative phenotype of mutant human immunodeficiency virus type 1 strains from nonpermissive cells by intravirion reverse transcription.

Authors:  G Dornadula; S Yang; R J Pomerantz; H Zhang
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

4.  Human immunodeficiency virus type 1 Vif protein is an integral component of an mRNP complex of viral RNA and could be involved in the viral RNA folding and packaging process.

Authors:  H Zhang; R J Pomerantz; G Dornadula; Y Sun
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

5.  Association of human immunodeficiency virus type 1 Vif with RNA and its role in reverse transcription.

Authors:  M Dettenhofer; S Cen; B A Carlson; L Kleiman; X F Yu
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

6.  Role of Vif in stability of the human immunodeficiency virus type 1 core.

Authors:  A Ohagen; D Gabuzda
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

7.  Vif and the p55(Gag) polyprotein of human immunodeficiency virus type 1 are present in colocalizing membrane-free cytoplasmic complexes.

Authors:  J H Simon; E A Carpenter; R A Fouchier; M H Malim
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

8.  Mitogen-activated protein kinase phosphorylates and regulates the HIV-1 Vif protein.

Authors:  X Yang; D Gabuzda
Journal:  J Biol Chem       Date:  1998-11-06       Impact factor: 5.157

Review 9.  HIV-1: fifteen proteins and an RNA.

Authors:  A D Frankel; J A Young
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

10.  The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.

Authors:  Ann M Sheehy; Nathan C Gaddis; Michael H Malim
Journal:  Nat Med       Date:  2003-10-05       Impact factor: 53.440

View more
  9 in total

1.  APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis.

Authors:  Holly A Sadler; Mark D Stenglein; Reuben S Harris; Louis M Mansky
Journal:  J Virol       Date:  2010-05-12       Impact factor: 5.103

2.  The cellular antiviral protein APOBEC3G interacts with HIV-1 reverse transcriptase and inhibits its function during viral replication.

Authors:  Xiaoxia Wang; Zhujun Ao; Liyu Chen; Gary Kobinger; Jinyu Peng; Xiaojian Yao
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

3.  Mass spectrometry analysis of HIV-1 Vif reveals an increase in ordered structure upon oligomerization in regions necessary for viral infectivity.

Authors:  Jared R Auclair; Karin M Green; Shivender Shandilya; James E Evans; Mohan Somasundaran; Celia A Schiffer
Journal:  Proteins       Date:  2007-11-01

Review 4.  HIV Genome-Wide Protein Associations: a Review of 30 Years of Research.

Authors:  Guangdi Li; Erik De Clercq
Journal:  Microbiol Mol Biol Rev       Date:  2016-06-29       Impact factor: 11.056

Review 5.  Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors.

Authors:  Simon Henriet; Gaëlle Mercenne; Serena Bernacchi; Jean-Christophe Paillart; Roland Marquet
Journal:  Microbiol Mol Biol Rev       Date:  2009-06       Impact factor: 11.056

6.  Requirements for nucleocapsid-mediated regulation of reverse transcription during the late steps of HIV-1 assembly.

Authors:  Pierre-Jean Racine; Célia Chamontin; Hugues de Rocquigny; Serena Bernacchi; Jean-Christophe Paillart; Marylène Mougel
Journal:  Sci Rep       Date:  2016-06-07       Impact factor: 4.379

7.  Mutational analysis of the HIV-1 auxiliary protein Vif identifies independent domains important for the physical and functional interaction with HIV-1 reverse transcriptase.

Authors:  Alexandra Kataropoulou; Chiara Bovolenta; Amalia Belfiore; Sonia Trabatti; Anna Garbelli; Simona Porcellini; Rossella Lupo; Giovanni Maga
Journal:  Nucleic Acids Res       Date:  2009-04-15       Impact factor: 16.971

8.  Vif is a RNA chaperone that could temporally regulate RNA dimerization and the early steps of HIV-1 reverse transcription.

Authors:  S Henriet; L Sinck; G Bec; R J Gorelick; R Marquet; J-C Paillart
Journal:  Nucleic Acids Res       Date:  2007-07-26       Impact factor: 16.971

9.  Structural analysis of viral infectivity factor of HIV type 1 and its interaction with A3G, EloC and EloB.

Authors:  Kauê Santana da Costa; Elcio Leal; Alberto Monteiro dos Santos; Anderson Henrique Lima e Lima; Cláudio Nahum Alves; Jerônimo Lameira
Journal:  PLoS One       Date:  2014-02-26       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.